Page last updated: 2024-12-06

pyromeconic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyromeconic acid: from herb Dengzhanhua; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68129
CHEMBL ID79857
SCHEMBL ID588597
SCHEMBL ID6991329
MeSH IDM0096224

Synonyms (38)

Synonym
CHEMBL79857 ,
4h-pyran-4-one, 3-hydroxy-
pyromeconic acid
nsc-78608
3-hydroxy-4h-pyran-4-one
nsc78608
3-hydroxy-4-pyrone
496-63-9
veyimqvtpxpuha-uhfffaoysa-
inchi=1/c5h4o3/c6-4-1-2-8-3-5(4)7/h1-3,7h
3-hydroxypyran-4-one
pyrocomenic acid
AKOS006283182
nsc 78608
8j0g2x46r7 ,
einecs 207-823-6
unii-8j0g2x46r7
FT-0674242
SCHEMBL588597
3-hydroxy-pyran-4(1h)-one
3-hydroxy-pyran-4(l h)-one
3-hydroxy-pyran-4-one
4-oxo-(4h)-pyran-3-yl alcohol
DTXSID7060091
pyromekonsaure
SY024796
mfcd09863957
SCHEMBL6991329
GS-0900
CS-D1527
AMY19288
SB12364
Q27270604
HY-N1997
bdbm50536112
pyromeconicacid
EN300-116571
Z1198235068
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))IC50 (µMol)23.80951.88004.68805.8600AID1635903
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)23.80950.00002.398310.0000AID1635903
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)IC50 (µMol)232.00005.00005.00005.0000AID1893771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
extracellular regionPolymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID24630Compound was tested for their chelating potential with gallium-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID24628Compound was tested for their chelating potential with Indium-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1635904Inhibition of 8-histidine tagged influenza virus H1N1 N-terminal PA endonuclease expressed in Escherichia coli BL21 cells at 200 uM using single-stranded 5'-FAM fluorophore/3'-TAMRA quencher)-labeled 17-mer ssDNA-oligomer substrate measured over 45 mins b2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fragment-Based Identification of Influenza Endonuclease Inhibitors.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1635903Inhibition of 8-histidine tagged influenza virus H1N1 N-terminal PA endonuclease expressed in Escherichia coli BL21 cells using single-stranded 5'-FAM fluorophore/3'-TAMRA quencher)-labeled 17-mer ssDNA-oligomer substrate measured over 45 mins by FRET ana2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fragment-Based Identification of Influenza Endonuclease Inhibitors.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1363739Inhibition of Influenza A (A/California/04/2009) (H1N1) clinical isolate N-terminal truncated PA endonuclease using 5'-FAM/3-TAMRA quencer labeled 17-mer ssDNA-oligo as substrate measured over 45 mins by FRET assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID1635905Inhibition of 8-histidine tagged influenza virus H1N1 N-terminal PA endonuclease expressed in Echerichia coli BL21 cells at 50 uM using single-stranded 5'-FAM fluorophore/3'-TAMRA quencher)-labeled 17-mer ssDNA-oligomer substrate measured over 45 mins by 2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Fragment-Based Identification of Influenza Endonuclease Inhibitors.
AID24629Compound was tested for their chelating potential with Iron-III complex determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
AID28931Logarithm of cumulative stability constant was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPĪ± Checkpoint.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID29379Acid dissociation constant (pKa2) was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID24627Compound was tested for their chelating potential (free ligand) determined by distribution coefficient method.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (18.75)18.7374
1990's5 (31.25)18.2507
2000's1 (6.25)29.6817
2010's4 (25.00)24.3611
2020's3 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.66 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]